Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence

Oncotarget

Volumn 7, Issue 38, 2016, Pages 62280-62291

  Ueda, Masami ^a,b   Iguchi, Tomohiro ^a   Masuda, Takaaki ^a   Nakahara, Yujiro ^b   Hirata, Hidenari ^a   Uchi, Ryutaro ^a   Niida, Atsushi ^c   Momose, Kota ^b   Sakimura, Shotaro ^a   Chiba, Kenichi ^c   Eguchi, Hidetoshi ^a   Ito, Shuhei ^a   Sugimachi, Keishi ^a,d   Yamasaki, Makoto ^b   Suzuki, Yutaka ^c   Miyano, Satoru ^c   Doki, Yuichiro ^b   Mori, Masaki ^b   Mimori, Koshi ^a  

^a KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Fukuoka City Hospital   (Japan)

Author keywords

Cell free DNA; Esophageal squamous cell carcinoma; Next generation sequencing; Somatic mutation; Tumor recurrence

Indexed keywords

CELL FREE DNA; CISPLATIN; DNA; DOCETAXEL; FLUOROURACIL; GENOMIC DNA; TUMOR MARKER; UNCLASSIFIED DRUG; CIRCULATING TUMOR DNA;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC MARKER; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MIDDLE AGED; NEXT GENERATION SEQUENCING; PLASMA; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; TUMOR VOLUME; BLOOD; DNA MUTATIONAL ANALYSIS; ESOPHAGUS TUMOR; EVALUATION STUDY; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PROCEDURES; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE; X-RAY COMPUTED TOMOGRAPHY;

AGED; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CIRCULATING TUMOR DNA; DNA MUTATIONAL ANALYSIS; ESOPHAGEAL NEOPLASMS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84991786942     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11409     Document Type: Article

References (29)

1. Enzinger PC and Mayer RJ. Esophageal cancer. N Engl J Med. 2003; 349: 2241-2252.
2. Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Miyazawa Y, Shiratori T, Uno T, Itoh H and Ochiai T. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003; 133: 24-31.
3. Abate E, DeMeester SR, Zehetner J, Oezcelik A, Ayazi S, Costales J, Banki F, Lipham JC, Hagen JA and DeMeester TR. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg. 2010; 210: 428-435.
4. Schwarzenbach H, Hoon DS and Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11:426-437.
5. Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J, Chin SF, Tsui DW, Marass F, Gale D, Ali HR, Shah P, Contente-Cuomo T, et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 2015; 6: 8760.
6. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, Shrager JB, Loo BW Jr, Alizadeh AA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014; 20: 548-554.
7. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov. 2015; 5: 1040-1048.
8. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS and Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486: 537-540.
9. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368: 1199-1209.
10. Takai E, Totoki Y, Nakamura H, Morizane C, Nara S, Hama N, Suzuki M, Furukawa E, Kato M, Hayashi H, Kohno T, Ueno H, Shimada K, et al. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep. 2015; 5: 18425.
11. Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban CA, Scharpf R, White JR, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015; 6: 7686.
12. Sawada G, Niida A, Uchi R, Hirata H, Shimamura H, Suzuki Y, Shiraishi Y, Chiba K, Imoto S, Takahashi Y, Iwaya T, Sudo T, Hayashi T, et al. The genomic landscape of Japanese esophageal squamous cell carcinoma. Gastroenterology. 2016; 150: 1171-1182.
13. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, Ma X, Liu L, Zhao Z, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014; 509: 91-95.
14. Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, Sato Y, Okuno Y, Varela AM, Ding LW, Garg M, Liu LZ, Yang H, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet. 2014; 46: 467-473.
15. Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun ZM, Zhang F, Zhao ZR, Li ZT, Liu ZY, Zhao YD, Sun J, Zhou CC, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 2014; 46: 1097-1102.
16. Uchi R, Takahashi Y, Niida A, Shimamura T, Hirata H, Sugimachi K, Sawada G, Iwaya T, Kurashige J, Shinden Y, Iguchi T, Eguchi H, Chiba K, et al. Integrated multiregional analysis proposing a new model of colorectal cancer evolution. PLoS Genet. 2016; 12: e1005778.
17. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, Heatley SL, Holmfeldt L, Collins-Underwood JR, Ma J, Buetow KH, Pui CH, Baker SD, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011; 471: 235-239.
18. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011; 471: 189-195
19. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, He M, Li Z, Sun X, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011; 43: 875-878
20. Kishimoto M, Kohno T, Okudela K, Otsuka A, Sasaki H, Tanabe C, Sakiyama T, Hirama C, Kitabayashi I, Minna JD, Takenoshita S and Yokota J. Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res. 2005; 11: 512-519.
21. Goodman RH and Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000; 14: 1553-1577.
22. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem Pharmacol. 2004; 68: 1145-1155.
23. Bannister AJ and Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 1996; 384: 641-643.
24. Ogryzko VV, Schiltz RL, Russanova V, Howard BH and Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996; 87: 953-959.
25. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA and Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer. 1994; 58: 480-487.
26. Zhang J, Xv Z, Wu X and Li K. Potential diagnostic value of serum p53 antibody for detecting esophageal cancer: a meta-analysis. PLoS One. 2012; 7: e52896.
27. McGranahan N and Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015; 28: 141.
28. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H and Ochiai T. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery. 2003; 133: 486-494.
29. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr. and Kinzler KW. Cancer genome landscapes. Science. 2013; 339: 1546-1558.